WAVE Life Sciences ROA 2024

WAVE Life Sciences Aktienanalyse

What does WAVE Life Sciences do?

WAVE Life Sciences Ltd is a biotechnology company dedicated to the development of nucleic acid preparations for the treatment of genetically inherited diseases. The company was founded in 2012 and is headquartered in Singapore. WAVE Life Sciences' business model is focused on developing specific nucleic acid sequences that can selectively silence or correct defective genes associated with various diseases. The company offers these sequences as therapeutics that enable personalized treatment for patients. The company utilizes a proprietary platform technology called "AVIENNA" to selectively silence or correct defective genes. "AVIENNA" aims to optimize the physical properties of nucleic acids to improve their effectiveness and duration of action. WAVE Life Sciences has three business areas: neurology, cardiovascular diseases, and metabolic diseases. In the neurology area, the company focuses on the development of therapeutics for the treatment of amyotrophic lateral sclerosis (ALS) and Huntington's disease. In the cardiovascular diseases area, the company is working on therapeutics for cardiovascular diseases such as heart attack, stroke, and atherosclerosis. In the metabolic diseases area, WAVE Life Sciences is focused on the development of therapeutics for rare metabolic diseases such as Crohn's disease and Pompe disease. The most well-known product in WAVE Life Sciences' pipeline is "WVE-120101", a therapeutic for the treatment of ALS. The drug has been developed to target mutations in the SOD1 gene that can lead to ALS. WVE-120101 is currently in clinical trials and has the potential to become the first approved medication for patients with ALS. WAVE Life Sciences also collaborates closely with other companies to exchange technologies and know-how. In 2018, the company entered into a strategic partnership with Takeda Pharmaceutical to jointly develop therapeutics for the treatment of gastrointestinal diseases. The partnership aims to leverage the strengths of both companies and accelerate the development of innovative therapeutics. Overall, WAVE Life Sciences has a promising portfolio of therapeutics that have the potential to improve the lives of patients with genetically inherited diseases. The company follows a systematic and scientifically-based strategy in drug development to ensure the effectiveness and safety of its products. With its innovative business model and dedicated research and development, WAVE Life Sciences is well positioned to achieve a leading position in the biotechnology industry in the future. WAVE Life Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding WAVE Life Sciences's Return on Assets (ROA)

WAVE Life Sciences's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing WAVE Life Sciences's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider WAVE Life Sciences's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in WAVE Life Sciences’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about WAVE Life Sciences Stock

What is the Return on Assets (ROA) of WAVE Life Sciences this year?

The Return on Assets (ROA) of WAVE Life Sciences is -0.21 undefined this year.

What was the ROA of WAVE Life Sciences compared to the previous year?

The ROA of WAVE Life Sciences has increased by -81.08% compared to the previous year.

What consequences do high ROA have for investors of WAVE Life Sciences?

A high ROA is advantageous for investors of WAVE Life Sciences, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in WAVE Life Sciences?

A low ROA can be unfavorable for investors of WAVE Life Sciences as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of WAVE Life Sciences affect the company?

An increase in ROA of WAVE Life Sciences can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of WAVE Life Sciences impact the company?

A reduction in the ROA of WAVE Life Sciences can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of WAVE Life Sciences?

Some factors that can influence the ROA of WAVE Life Sciences include revenue, operating costs, asset structure, and industry average.

Why is the ROA of WAVE Life Sciences important for investors?

The ROA of WAVE Life Sciences is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can WAVE Life Sciences take to improve ROA?

To improve ROA, WAVE Life Sciences can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does WAVE Life Sciences pay?

Over the past 12 months, WAVE Life Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, WAVE Life Sciences is expected to pay a dividend of 0 USD.

What is the dividend yield of WAVE Life Sciences?

The current dividend yield of WAVE Life Sciences is .

When does WAVE Life Sciences pay dividends?

WAVE Life Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of WAVE Life Sciences?

WAVE Life Sciences paid dividends every year for the past 0 years.

What is the dividend of WAVE Life Sciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is WAVE Life Sciences located?

WAVE Life Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von WAVE Life Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of WAVE Life Sciences from 6/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/6/2024.

When did WAVE Life Sciences pay the last dividend?

The last dividend was paid out on 6/6/2024.

What was the dividend of WAVE Life Sciences in the year 2023?

In the year 2023, WAVE Life Sciences distributed 0 USD as dividends.

In which currency does WAVE Life Sciences pay out the dividend?

The dividends of WAVE Life Sciences are distributed in USD.